Showing results (11-20 of 29) with videos related to
Sort By:
Pageof 3
British Journal of Haematology|February 24, 2005
Activity of sirolimus in patients with myelodysplastic syndrome--results of a pilot studyU Platzbecker, M Haase, R Herbst, et al.Leukemia|February 17, 2006
Reduced intensity conditioning allows for up-front allogeneic hematopoietic stem cell transplantation after cytoreductive induction therapy in newly-diagnosed high-risk acute myeloid leukemiaU Platzbecker, C Thiede, M Füssel, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 15, 2014
Optimization of rituximab for the treatment of DLBCL (I): dose-dense rituximab in the DENSE-R-CHOP-14 trial of the DSHNHLN Murawski, M Pfreundschuh, S Zeynalova, et al.Annals of Hematology|March 22, 2002
Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphomaM Hänel, N Kröger, S Sonnenberg, et al.Annals of Hematology|July 20, 2000
ASHAP--an effective salvage therapy for recurrent and refractory malignant lymphomasM Hänel, N Kröger, M M Hoffknecht, et al.Annals of Hematology|June 24, 2016
Health care setting and severity, symptom burden, and complications in patients with Philadelphia-negative myeloproliferative neoplasms (MPN): a comparison between university hospitals, community hospitals, and office-based physiciansA Kaifie, S Isfort, N Gattermann, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 30, 2015
Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML--long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL)A Thiel, J Schetelig, W Pönisch, et al.Journal of Hematology & Oncology|March 6, 2016
Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registryA Kaifie, M Kirschner, D Wolf, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 26, 2017
Allogeneic hematopoietic cell transplantation in intermediate risk acute myeloid leukemia negative for FLT3-ITD, NPM1- or biallelic CEBPA mutationsK Heidrich, C Thiede, K Schäfer-Eckart, et al.Journal of Cancer Research and Clinical Oncology|September 27, 2015
Long-term follow-up of the AML97 study for patients aged 60 years and above with acute myeloid leukaemia: a study of the East German Haematology and Oncology Study Group (OSHO)C Kahl, R Krahl, C Becker, et al.Pageof 3